晚期非小细胞肺癌4种化疗方案的药物经济学评价

目的：探讨晚期非小细胞肺癌不同治疗方案的临床疗效和经济学效果。方法：收集某院2012-2015年99例符合要求的晚期非小细胞肺癌患者，根据不同治疗方法分为4组，用药物经济学对成本与效果进行分析，对4组治疗方案进行回顾性分析。A组：多西他赛+顺铂；B组：多西他赛+卡铂；C组：培美曲塞+顺铂；D组：培美曲塞+卡铂。结果：4组化疗方案的有效率分别为40.54%，31.58%，57.89%，54.17%。化疗一个疗程住院总费用分别为6 307.96元，5 356.51元，11 980.83元，11 387.94元。在B方案的基础上，每增加一个单位效果，A方案、C方案、D方案所需要的成本分别为106.19元，251.78，267.00元。结论：从成本-效果分析，A方案为治疗晚期非小细胞肺癌的较合理的方案。

Pharmacoeconomics evaluation of four different chemotherapy regimens against advanced non small cell lung cancer

OBJECTIVE Pharmacoeconomics evaluation was performed by cost-effective analysis to provide a basis for selecting appropriate chemotherapeutic regimens.METHODS A total of 99 patients with advanced non small cell lung cancer were enrolled from a hospital, and divided into four groups according to methods of treatment and analysis by pharmacoeconomic cost-effectiveness method, and retrospective analysis was also applied. Group A, docetaxel combined with cisplatin; group B, docetaxel combined with carboplatin; group C, pemetrexed combined with cisplatin; group D, pemetrexed combined with carboplatin.RESULTS Effective rates of four regimes were 40.54%, 31.58%, 57.89% and 31.58%, respectively. Costs of chemotherapeutic regimens were 6 307.96, 5 356.51, 11 980.83 and 5 356.51 yuan, respectively. Based on group B, for each unit of efficacy increased, costs in regimen A, C, D were increased 106.19, 251.78 and 267.00 yuan respectively.CONCLUSION Regimen B against advanced non small cell lung cancer is more appropriate considering the cost and effect.